Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

The New Daily

Dow Jones Falls On Peak-Rate Uncertainty; QCOM Falls While ETSY, RUN Rise After Earnings

The Dow Jones rose ahead of a Fed rate hike. Fed Chief Powell's comments suggested a rate pause. Eli Lilly surged after reporting a breakthrough Alzheimer's treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

Evening Standard

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The National (Scotland)

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

The Independent UK

Eli Lilly Hits A Record-Smashing $409 Billion Market Cap Following Its Alzheimer's Win

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug found

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

The Independent UK

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Investors Business Daily

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Daily Record

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

The Independent UK

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Barchart

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

Investors Business Daily

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Manager Of Top T. Rowe Price Fund Is Still 'Pretty Cautious'

Looking for a go-anywhere stock fund that isn't trapped in a style box and can buy stocks of all sizes and styles? Well, Justin White's T. Rowe Price All-Cap Opportunities Fund checks all those boxes.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

The Guardian - UK

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

Axios

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Chicago Sun-Times

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations